|Application ||WB, IHC-P, E|
|Calculated MW||28897 Da|
|Antigen Region||191-222 aa|
|Other Names||Homeobox protein MSX-2, Homeobox protein Hox-8, MSX2, HOX8|
|Target/Specificity||This Msx2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 191-222 amino acids from the C-terminal region of human Msx2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Msx2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a transcriptional regulator in bone development. Represses the ALPL promoter activity and antogonizes the stimulatory effect of DLX5 on ALPL expression during osteoblast differentiation. Probable morphogenetic role. May play a role in limb-pattern formation. In osteoblasts, suppresses transcription driven by the osteocalcin FGF response element (OCFRE). Binds to the homeodomain-response element of the ALPL promoter.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the muscle segment homeobox gene family. The encoded protein is a transcriptional repressor whose normal activity may establish a balance between survival and apoptosis of neural crest-derived cells required for proper craniofacial morphogenesis. The encoded protein may also have a role in promoting cell growth under certain conditions and may be an important target for the RAS signaling pathways. Mutations in this gene are associated with parietal foramina 1 and craniosynostosis type 2.
Shao,J.S., Ann. N. Y. Acad. Sci. 1117, 40-50 (2007)
Han,J., Mech. Dev. 124 (9-10), 729-745 (2007)
Ghassibe,M., Eur. J. Pediatr. 165 (10), 734-735 (2006)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.